...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current diabetes reports. >Rational drug design and PPAR agonists.
【24h】

Rational drug design and PPAR agonists.

机译：合理的药物设计和PPAR激动剂。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Insulin resistance is a characteristic biological abnormality associated with type 2 diabetes, and is a key component of the metabolic syndrome, a condition in which an altered glucose control is associated with dyslipidemia, hypertension, and obesity. Thiazolidinediones (TZDs), a new class of oral drugs used for the treatment of type 2 diabetes, reduce insulin resistance via an action on peroxisome proliferator-activated receptors. Although the current use of TZDs is largely limited to the treatment of patients with diabetes, as recommended in the package insert, it is foreseeable that as the metabolic syndrome becomes a better understood clinical condition their use may be extended to the treatment of this cluster of disorders. The aim of the present article is to review the mechanism of action of TZDs, discuss the rationale for their use in the clinical setting, and provide an update on novel pharmacologic agents that, although not yet available for the treatment of diabetes, are likely to further enrich the repertoire of antidiabetic drugs in the very near future.
机译：胰岛素抵抗是与2型糖尿病相关的特征性生物学异常，并且是代谢综合征的关键组成部分，其中代谢异常的葡萄糖控制与血脂异常，高血压和肥胖症相关。噻唑烷二酮（TZDs）是用于治疗2型糖尿病的新型口服药物，它通过对过氧化物酶体增殖物激活受体的作用来降低胰岛素抵抗。尽管目前TZD的使用主要限于糖尿病患者的治疗，如包装说明书中所建议，但可以预见的是，随着新陈代谢综合症的临床病情得到更好的理解，它们的使用可能会扩展到该类糖尿病的治疗上。疾病。本文的目的是回顾TZD的作用机理，讨论其在临床中使用的原理，并提供有关新型药物的最新信息，尽管目前尚无法用于糖尿病的治疗。在不久的将来进一步丰富了抗糖尿病药的种类。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号